WST
West Pharmaceutical Services, Inc. · Healthcare · Medical Instruments & Supplies
Last
$254.35
+$5.33 (+2.14%) 4:00 PM ET
After hours $254.34 −$0.01 (−0.00%) 8:06 PM ET
Prev close $249.02
Open $248.06
Day high $254.35
Day low $247.06
Volume 741,201
Avg vol 1,153,323
Mkt cap
$18.32B
P/E ratio
37.46
FY Revenue
$3.07B
EPS
6.79
Gross Margin
35.91%
Sector
Healthcare
AI report sections
WST
West Pharmaceutical Services, Inc.
No AI report section text found yet for this symbol.
Volume vs average
Intraday (cumulative)
−13% (Below avg)
Vol/Avg: 0.87×
RSI
51.01 (Neutral)
Neutral (40–60)
MACD momentum
Intraday
+0.13 (Strong)
MACD: 0.51 Signal: 0.38
Short-Term
+1.66 (Strong)
MACD: -2.13 Signal: -3.80
Long-Term
+1.24 (Strong)
MACD: -7.45 Signal: -8.68
Intraday trend score 60.00

Latest news

WST 12 articles Positive: 8 Neutral: 1 Negative: 3
Positive Investing.com • Timothy Fries
Iron Mountain Projects Double-Digit Growth in 2026

Iron Mountain, US Foods, and West Pharmaceutical Services reported strong Q4 2025 earnings. Iron Mountain posted record results with 16.6% revenue growth driven by data center and digital services, projecting 10-13% revenue growth for 2026. US Foods achieved 178.8% net income growth despite softer economic conditions, while West Pharmaceutical delivered 7.5% revenue growth with strong performance in high-value product components.

IRM USFD WST earnings reports Q4 2025 data center growth revenue guidance operational efficiency
Sentiment note

Delivered strong results with 7.5% revenue growth exceeding expectations, adjusted diluted EPS of $2.04 surpassing guidance, and double-digit organic revenue growth in High-Value Product Components segment. 2026 guidance projects 5-7% organic growth and 7.7-12.5% EPS growth.

Negative Benzinga • Nabaparna Bhattacharya
DraftKings, Abbott, And Applovin Are Among Top 10 Large Cap Losers Last Week (Jan. 19-Jan. 23): Are the Others in Your Portfolio?

Ten large-cap stocks experienced significant declines during the week of January 19-23, 2026. AeroVironment led losses with a 19.45% drop following a government stop work order. DraftKings fell 14.4% due to Massachusetts blocking sports-related contracts, while Abbott declined 12.23% after missing earnings expectations. Other major losers included AppLovin (14.68%), Shopify (13.51%), Flutter Entertainment (13.07%), and West Pharmaceutical Services (13.27%).

AVAV DKNG ABT APP large-cap losers stock market decline earnings miss regulatory action
Sentiment note

Slumped 13.27% during the week with no specific catalyst mentioned

Positive Benzinga • Vandana Singh
AbbVie Gets Tariff Relief, Pledges $100 Billion, Lower Prices For Key Medicines

AbbVie announced a voluntary agreement with the Trump administration to lower drug prices for Medicaid while pledging $100 billion in U.S.-based R&D and capital investments over the next decade. In exchange, the company receives tariff exemptions and protection from future pricing mandates. AbbVie also announced a $650 million licensing deal with RemeGen for cancer drug RC148 and agreed to acquire a West Pharmaceutical Services manufacturing facility in Arizona for $175 million.

ABBV JNJ WST tariff relief drug pricing pharmaceutical investment manufacturing acquisition licensing agreement
Sentiment note

Company is divesting a manufacturing facility and associated IP to AbbVie for $175 million, providing capital and allowing focus on core operations.

Neutral GlobeNewswire Inc. • Researchandmarkets.Com
$1.22 Bn Cell Therapy Packaging Market Industry Trends and Global Forecasts to 2035: Growth Driven by Shift From Broad-Spectrum Treatments to Personalized Therapeutic Development

The global cell therapy packaging market is projected to grow from $404 million in 2025 to $1.22 billion by 2035, driven by personalized cell therapies and technological innovations in packaging solutions.

TMO WST cell therapy packaging market personalized therapeutics cryogenic storage AI automation
Sentiment note

Listed as a market player without detailed growth indicators

Positive GlobeNewswire Inc. • Towards Packaging
Cell Therapy Packaging Market Trends and Companies Data 2025-35

The global cell therapy packaging market is projected to grow from $419.57 million in 2025 to $1.27 billion by 2034, driven by increasing demand for cell and gene therapies, technological advancements, and specialized packaging solutions.

WST BLFS cell therapy packaging market growth biotechnology cold chain logistics personalized medicine
Sentiment note

Provides specialized primary containment solutions for cryogenic storage, positioning them well in the growing cell therapy packaging market

Positive GlobeNewswire Inc. • Towards Packaging
Medical Flexible Packaging Market Size, Trends, Segments and Regional Data (NA/EU/APAC/LA/MEA) 2025-2035

The global medical flexible packaging market is projected to grow from USD 21.48 billion in 2025 to USD 34.78 billion by 2034, with a 5.5% CAGR. Key growth drivers include rising pharmaceutical needs, sustainability focus, and increasing chronic disease prevalence.

MMM WST DD GRRMY medical packaging flexible packaging pharmaceuticals healthcare
Sentiment note

Specializes in injectable drug packaging and delivery systems, showing strategic focus in a growing market segment

Positive The Motley Fool • Eric Volkman
Why West Pharmaceutical Services Stock Was Blasting Higher on Thursday

West Pharmaceutical Services reported strong Q3 2025 earnings, beating analyst expectations with nearly 8% year-over-year sales growth and raising full-year guidance, leading to an 11% stock price increase.

WST pharmaceutical services earnings report stock performance quarterly results
Sentiment note

Company exceeded analyst expectations with 8% sales growth, 3% net income increase, raised full-year revenue and profitability guidance, and experienced an 11% stock price surge

Positive Benzinga • Vandana Singh
West Pharma Soars After Q3 Beat, Lifts Outlook On GLP-1 Demand

West Pharmaceutical Services reported strong Q3 earnings, beating analyst estimates with $1.96 per share and raising fiscal 2025 guidance, driven by robust demand for GLP-1 product components.

WST pharmaceutical earnings GLP-1 packaging guidance
Sentiment note

Exceeded Q3 earnings expectations, raised full-year guidance, achieved double-digit growth in HVP Components business, and received positive analyst commentary

Negative GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.
WEST PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into West Pharmaceutical Services, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Law firm investigating potential claims against West Pharmaceutical Services for allegedly misleading investors about business performance, customer demand, and product margins during February 2023-2025 period.

WST pharmaceutical investigation stock fiduciary duties SmartDose
Sentiment note

Stock dropped 38% after revealing weak revenue forecasts, loss of major customers, margin-dilutive product performance, and potential restructuring risks

Positive GlobeNewswire Inc. • Towards Packaging
Parenteral Packaging Market to Worth USD 20.12 Bn by 2034

The global parenteral packaging market is projected to grow from $13.39 billion in 2025 to $20.12 billion by 2034, driven by rising demand for prefilled syringes, advanced self-administration devices, and increasing chronic disease prevalence.

GRRMY WST parenteral packaging prefilled syringes pharmaceutical packaging medical packaging healthcare innovation
Sentiment note

Mentioned as a top market player in a growing industry with strong future potential

Positive The Motley Fool • Na
West Pharma EPS Jumps 22 Percent in Q2

West Pharmaceutical Services reported strong Q2 2025 financial results, beating earnings and revenue estimates, with significant growth in proprietary products and raised full-year guidance driven by high-value drug delivery components and regulatory-driven conversions.

WST pharmaceutical drug delivery earnings revenue healthcare medical devices
Sentiment note

Exceeded Q2 earnings and revenue expectations, raised full-year guidance, demonstrated 10.7% growth in Proprietary Products sales, expanded operating profit margins, and showed strong performance in high-value product components and delivery devices

Negative GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.
WEST ALERT: Bragar Eagel & Squire, P.C. is Investigating West Pharmaceutical Services, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Law firm investigating potential claims against West Pharmaceutical Services for allegedly misleading investors about business performance, product margins, and customer relationships during February 2023-2025 period.

WST pharmaceutical investigation shareholder rights class action financial disclosure
Sentiment note

Stock dropped 38% after revealing weak revenue forecasts, loss of major customers, margin-dilutive product performance, and potential restructuring risks

News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal